Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer

Veterinary and Comparative Oncology

Volumn 10, Issue 2, 2012, Pages 102-112

  Leach, T N ^a   Childress, M O ^a   Greene, S N ^b   Mohamed, A S ^a   Moore, G E ^a   Schrempp, D R ^a   Lahrman, S R ^a   Knapp, D W ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b VCA Aurora Animal Hospital   (United States)

^c Purdue University   (United States)

Author keywords

Antiangiogenesis; Chemotherapy; Chlorambucil; Metronomic; Oncology

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; DOG; DOG DISEASE; FEMALE; MALE; METRONOMIC DRUG ADMINISTRATION; NEOPLASM; PROSPECTIVE STUDY;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHLORAMBUCIL; DOG DISEASES; DOGS; FEMALE; MALE; NEOPLASMS; PROSPECTIVE STUDIES;

CANIS FAMILIARIS;

EID: 84860328562     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2011.00280.x     Document Type: Article

References (57)

1. Hanfeldt P, Folkman J and Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. Journal of Theoretical Biology 2003; 220: 545-554.
2. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS and Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Research 2000; 60: 1878-1886.
3. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A and Kroemer G. The anticancer immune response: indispensable for therapeutic success? Journal of Clinical Investigations 2008; 118: 1991-2001.
4. González-Billalabeitia E, Calzas J, Castellano D, Mendiola C, Bezares S, Velentin V, Hornedo J, Ciruelo E and Cortés-Funes H. Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer. The Breast Journal 2009; 15: 551-553.
5. Samaritani R, Corrado G, Vizza E and Sbiroli C. Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. Biomed Central Cancer 2007; 7: 65.
6. Nicolini A, Mancini P, Ferrari P, Anselmi L, Tartarelli G, Bonazzi V, Carpi A and Giardino R. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomedicine & Pharmacotherapy 2004; 58: 447-450.
7. Glode LM, Barqawi A, Crighton F, Crawford ED and Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003; 98: 1643-1648.
8. Krzyzanowska MK, Tannock IF, Lockwood G, Knox J, Moore M and Bjarnason GA. Phase II trial of continuous low dose cyclophosphamide and celecoxib in patients with progressing advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology 2007; 60: 135-141.
9. Allegrini G, Falcone A, Fioravanti A, Barletta MT, Orlandi P, Loupakis F, Cerri E, Masi G, Di Paola A, Kerbel RS, Danesi R, Del Tacca M and Bocci G. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal patients. British Journal of Cancer 2008; 98: 1312-1319.
10. Kakolyris S, Samonis G, Koukourakis M, Vlachonicolis I, Chalkiadakis G, Kalbakis K, Souglakos I, Agelaki S and Toloudis P. Treatment of non-small cell lung cancer with prolonged oral etoposide. American Journal of Clinical Oncology 1998; 21: 505-508.
11. Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La Placa M, Sciandivasci A, Paolelli L, Pascucci A, Rossi M, Di Bisceglie M, Giorgi G, Gotti G and Francini GA. Novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncology Reports 2006; 16: 133-140.
12. Niitsu N and Umeda M. Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma. American Journal of Clinical Oncology 1997; 20: 311-314.
13. Rubie H, Coze C, Plantaz D, Munzer C, Defachelles AS, Bergeron C, Thomas C, Chastagner P, Valteau-Couanet D, Michon J, Mosseri V and Hartmann O. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy. British Journal of Cancer 2003; 89: 1605-1609.
14. Sterba J, Pavelka Z, Andre N, Ventruba J, Skotakova J, Bajciova V, Bronisova D, Dubska L and Valik D. Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy. Pediatric Blood Cancer 2010; 54: 616-617.
15. Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J and Laforme A, Black PMcL, Folkman J, Kieran M, and Wen PY. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-Oncology 2007; 9: 354-363.
16. Mi Rim Choi L, Rood B, Kamani N, La Fond D, Packer RJ, Santi MR and Macdonald TJ. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatric Blood Cancer 2008; 50: 970-975.
17. Stempak D, Seely D and Baruchel S. Metronomic dosing of chemotherapy: applications in pediatric oncology. Cancer Investigation 2006; 24: 432-443.
18. th edn., SJ Withrow and DM Vail, eds., St. Louis, Saunders, Elsevier, 2007: 540-567.
19. th edn., SJ Withrow and DM Vail, eds., St. Louis, Saunders, Elsevier, 2007: xv-xvii.
20. Knapp DW. Animal models: naturally occurring canine urinary bladder cancer. In: Textbook of Bladder Cancer, SP Lerner, MP Schoenberg and CN Sternberg, eds., Oxon, Taylor and Francis, 2006: 171-175.
21. Dhawan D, Craig BA, Cheng L, Snyder PW, Mohammed SI, Stewart JC, Zheng R, Loman R, Foster RS and Knapp DW. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Molecular Cancer Therapeutics 2010; 9: 1371.
22. Elmslie RE, Glawe P and Dowe SP. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. Journal of Veterinary Internal Medicine 2008; 26: 1373-1379.
23. Lana S, U'ren L, Plaza S, Elmslie R, Gustafson D, Morley P and Dow S. Continuous low-dose oral chemotherapy for adjuvant therapy for splenic hemangiosarcoma in dogs. Journal of Veterinary Internal Medicine 2007; 21: 764-769.
24. Leifer CE. Chronic lymphocytic leukemia in the dog: 22 cases (1974-1984). Journal of the Veterinary Medical Association 1986; 189: 214-217.
25. MacKewan EG and Hurvitz AI. Diagnosis and management of monoclonal gammopathies. Veterinary Clinics of North America Small Animal Practice 1977; 7: 119-132.
26. th edn., SJ Withrow and DM Vail, eds., St. Louis, Saunders, Elsevier, 2007: 769-784.
27. Silvennoinen R, Malminiemi K, Malminiemi O, Seppälä E and Vilpo J. Pharmacokinetics of chlorambucil in patients with chronic lymphocytic leukemia: comparison of different days, cycles and doses. Pharmacology & Toxicology 2000; 87: 223-228.
28. Newell DR, Calvert AH and Harrap KR. Studies on the pharmacokinetics of chlorambucil and prednimustine in man. British Journal of Clinical Pharmacology 1983; 15: 253-258.
29. Alberts DS, Chang SY, Chen HSG, Larcom BJ and Jones SE. Pharmacokinetics and metabolism of chlorambucil in man: a preliminary case report. Cancer Treatment Review 1979; 6(Suppl.): 9-17.
30. McLean A, Woods RL, Catovsky D and Farmer PB. Pharmacokinetics and metabolism of chlorambucil in patients with malignant disease. Cancer Treatment Review 1979; 6(Suppl.): 33-42.
31. Godeneche D, Madelmont JC, Moreau MF, Plagne R and Meyneil G. Comparative physio-chemical properties, biological and effects and disposition in mice of four nitrogen mustards. Cancer Chemotherapy and Pharmacology 1980; 5: 1-9.
32. McLean A, Newell D and Baker G. The metabolism of chlorambucil. Biochemical Pharmacology 1976; 25: 2331-2335.
33. Schmidt A, Bölck B, Jedig M, Seinritz D, Balszuweit F, Kehe K and Bloch W. Nitrogen mustard (chlorambucil) has a negative influence on early vascular development. Toxicology 2009; 263: 32-40.
34. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y and Kerbel RS. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Research 2003; 63: 4342-4346.
35. Veterinary Co-Operative Oncology Group. Veterinary co-operative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats version 1.0. Veterinary and Comparative Oncology 2004; 2: 194-213.
36. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute 2000; 92: 205-216.
37. th edn., VT DeVita, S Hellman and SA Rosenberg, eds., Philadelphia, Lippincott Williams & Wilkins, 2005: 473-478.
38. Shirakawa K, Furuhata S, Watababe I, Hayase H, Shimizu A, Ikarashi Y, Yoshida T, Terada M, Hashimoto D and Wakasugi H. Induction of vasculogenesis in breast cancer models. British Journal of Cancer 2002; 87: 1454-1461.
39. Veltman JD, Lambers MEH, van Nimwegan M, de Jong S, Hendriks RW, Hoogsteden HC, Aerts JGJV and Hegmans JPJJ. Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity. Journal of Biomedicine and Biotechnology 2010; Article ID 798467.
40. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunological Reviews 2001; 182: 18-32.
41. th edn., SJ Withrow and DM Vail, eds., St. Louis, Saunders, Elsevier, 2007: 291-306.
42. Knapp DW, Glickman NW, Widmer WR, DeNicola DB, Adams LG, Kuczek T, Bonney PL, DeGortari AE, Han C and Glickman LT. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemotherapy and Pharmacology 2000; 46: 221-226.
43. Kerbel RS and Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nature Reviews Cancer 2004; 4: 423-436.
44. Jain RK. Taming vessels to treat cancer. Scientific American Special Edition 2008; 18: 64-71.
45. Hampton T. Antiangiogenic therapy a two-trick pony? Journal of the American Medical Association 2005; 293: 1051.
46. Fukumura D and Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvascular Research 2007; 74: 72-84.
47. Jain RK. A new target for tumor therapy. The New England Journal of Medicine 2009; 360: 2669-2671.
48. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nature Reviews Cancer 2008; 8: 309-316.
49. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nolè F, Viale G and Goldhirsch A. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Annals of Oncology 2006; 17: 232-238.
50. Stempak D, Seely D, Koren G and Baruchel S. Metronomic dosing of chemotherapy: applications in pediatric oncology. Cancer Investigation 2006; 24: 432-443.
51. Görn M, Habermann C, Anige M, Thöm I, Schuch G, Andritzky B, Brandl S, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C and Laack E. A pilot study of docetaxel and trofosfamide as second line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie 2008; 31: 185-189.
52. Taylor F, Gear R, Hoather T and Dobson J. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumors: 21 cases. Journal of Small Animal Practice 2009; 50: 284-289.
53. Rusk A, McKeegan E, Haviv F, Majest S, Henkin J and Khanna C. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clinical Cancer Research 2006; 12: 7444-7455.
54. th edn., SJ Withrow and DM Vail, eds., St. Louis, Saunders, Elsevier, 2007: 785-795.
55. Lawler J and Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. The International Journal of Biochemistry & Cell Biology 2004; 36: 1038-1045.
56. Armstrong LC and Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biology 2003; 22: 63-71.
57. Bocci G, Francia G, Man S, Lawler J and Kerbel RS. Thrombospondin-1 a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proceedings of the National Academy of Science of the United States of America 2003; 100: 12917-12922.